RecruitingNot ApplicableNCT05321316
Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma
Sponsor
Peking University Cancer Hospital & Institute
Enrollment
20 participants
Start Date
May 31, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
To evaluate the ability of \[68Ga\]N188 to detect nectin-4 overexpression in patients with urothelial carcinoma, especially in patients with recurrent or advanced bladder cancer.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called 18F-FDG for people with urothelial carcinoma. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUG18F-FDG
All study participants will undergo one 18F-FDG PET/CT scan.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05321316
Related Trials
DBC-664 in Adult Patients With Solid Tumors
NCT077050353 locations
A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
NCT064054251 location
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
NCT07421700115 locations
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
NCT04879329221 locations
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
NCT0709049930 locations